Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Bupropion is an atypical antidepressant drug that is the only nonnicotine‐based prescription medicine approved for smoking cessation by the Food and Drug Administration. The aim of the present experiments was to investigate the effects of bupropion (5–40 mg/kg) on the reinforcing properties of nicotine and food in rats. The effects of bupropion were studied under two schedules of reinforcement: a fixed ratio 5 time‐out 20‐sec (FR5 TO20 s) and a progressive ratio (PR). Rats were trained to respond for nicotine (0.01 or 0.03 mg/kg/infusion, free base) or food under the FR5 TO20 s schedule. Pretreatment with the highest dose of bupropion (40 mg/kg) resulted in a significant reduction (∼50%) of nicotine intake in rats self‐administering 0.03 mg/kg/infusion of nicotine. The same dose of bupropion also decreased (∼40%) the self‐administration of 0.01 mg/kg/infusion of nicotine, but this effect did not reach statistical significance. Pretreatment with bupropion slightly (∼15%) reduced responding for food under the FR5 TO20 s schedule. Finally, pretreatment with bupropion did not affect the self‐administration of nicotine (0.03 mg/kg/infusion) under a PR schedule, but dose‐dependently increased responding for food under the same PR schedule. These findings indicate that a high dose of bupropion decreases the reinforcing properties of nicotine as measured under an FR schedule, while having no apparent effects on breaking points for nicotine under a PR schedule that reflects both the reinforcing properties and the motivation to obtain nicotine. Synapse 50:20–28, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“The second is treatment with the antidepressant bupropion (Ahluwalia et al., 2002; George et al., 2002; Hurt et al., 1997; Hays et al., 2001; Jorenby et al., 1999; Tashkin et al., 2001).”
Koob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
Wise, R. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00965-0 · Cited by 881 · cited 1×
“Moreover, both nicotine and bupropion increased dopamine levels in the medial prefrontal cortex, a brain area that has been implicated in the rewarding effects of drugs of abuse (Drew et al., 2000; Piacentini et al., 2003; Wise, 2002).”
Salamone, J. D., & Correa, M. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00282-6 · Cited by 817
Corrigall, W. A., Coen, K. M., & Adamson, K. L. (1994) · Brain Research · doi:10.1016/0006-8993(94)90401-4 · Cited by 740 · cited 1×
“…dihydro- -erythroidine and the 7 nicotinic acetylcholine receptor antagonist methyllycaconitine decreased the self-administration of nicotine, which is indicative of a decrease in the rewarding properties of nicotine (Corrigall et al., 1994; Markou and Paterson, 2001; Watkins et al., 1999).”
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
Mansvelder, H. D., Keath, J. R., & McGehee, D. S. (2002) · Neuron · doi:10.1016/s0896-6273(02)00625-6 · Cited by 701 · cited 2×
“Stimulation of neuronal nicotinic acetylcholine receptors induces the activation of dopaminergic neurons in the ventral tegmental area (Mansvelder et al., 2002), resulting in an enhanced release of dopamine in the nucleus accumbens (Schilstrom et al., 1998).”
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal
S. Watkins, G. F. K. (2000) · Nicotine & Tobacco Research · doi:10.1080/14622200050011277 · Cited by 424
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Fryer, J. D., & Lukas, R. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37928-5 · Cited by 283 · cited 1×
“Bupropion also blocks nicotinic acetylcholine receptors (Fryer and Lukas, 1999; Slemmer et al., 2000) and might therefore reduce the rewarding properties of nicotine via blockade of these receptors in the ventral tegmental area.”
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“The latter result is contrary to what would be expected, given the findings of (Bruijnzeel and Markou, 2003) and highlights the complex effects of the bupropion on reward processing.”
BackgroundResultPierce, R. C., & Kumaresan, V. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.016 · Cited by 913
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
“…cessation aid, increases dopamine in the nucleus accumbens and has inconsistent effects on nicotine self-administration; eg, Paterson et al, 2007; Bruijnzeel and Markou, 2003), the strong a priori hypothesis, as well as the wide acceptance and trust in the construct validity of these…”
Self-citationDwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Metadata
- Authors
- Bruijnzeel, A. W., & Markou, A.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2003-07
- Volume
- 50
- Issue
- 1
- Pages
- 20-28
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2083739499
- Cited by
- 143
- References
- 15
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. https://app.cochat.ai/papers/10.1002/syn.10242
- The paper
- Bruijnzeel, A. W., & Markou, A. (2003). Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse. https://doi.org/10.1002/syn.10242
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.